- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02447783
Effect of Long Term Cocoa Flavanol Intake on Blood Pressure and Platelet Function in Healthy Adults, Part 2
May 24, 2017 updated by: University of California, Davis
Effect of Cocoa Flavanol Intake on Blood Pressure and Platelet Function in Healthy Adults, Part 2
Flavanols are plant-derived compounds commonly present in the human diet.
Examples of flavanol-containing foods and beverages are apples, chocolate, tea, wine, berries, pomegranate and nuts.
The consumption of flavanol-containing foods and beverages has been associated with improvements in cardiovascular health.
In this study, the investigators hope to learn more about the effects of long term consumptions of cocoa flavanols on blood pressure, platelet function and other metabolic parameters in healthy humans.
This study is a continuation of a previous study investigating the consumptions of increasing amounts of cocoa flavanols on blood pressure, platelet function and other metabolic parameters in healthy humans
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
75
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Davis, California, United States, 95616
- Ragle Human Nutrition Research Center, Department of Nutrition at UC Davis
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 30-55 years old
- A normal blood chemistry and liver function
- BMI < 30 kg/m2
- previously consumed cocoa and peanut products, with no adverse reactions
Exclusion Criteria:
- A history of cardiovascular disease, stroke, hypertension, renal, hepatic, or thyroid disease, GI tract disorders, previous GI surgery, metabolic syndrome, diabetes, taking cholesterol-lowering medication, hormone replacement therapy, antioxidant supplements, on aspirin therapy or taking anticoagulants, or on a medically prescribed diet.
- Allergies to nuts, cocoa and chocolate products
- Vegetarian, Vegan, food faddists, individuals using non-traditional diets, on a weight loss diet or using herbal dietary supplements
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Control, Flavanol-free intervention
Intake of flavanol-free, macro- and micro-nutrient matched control capsules
|
Cocoa-based, flavanol-free, control-matched capsules consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
|
|
Active Comparator: CF intervention
Intake of capsules containing Mars Cocoa Extract Capsules manufactured by the Cocoapro® process and providing 500 mg of cocoa flavanols per capsule
|
Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 500 mg of cocoa flavanols per capsule consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in blood pressure
Time Frame: Baseline (day 0) and 6,12 and 14 weeks after intervention
|
Blood pressure will be measured using standard techniques.
|
Baseline (day 0) and 6,12 and 14 weeks after intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in platelet function
Time Frame: Baseline and 6, 12 and 14 weeks after intervention
|
Platelet function will be determined using the PFA-100® analyzer (Dade Behring International, Miami, FL) with collagen-epinephrine (CEPI)- and collagen-ADP (CADP) stimulation.
|
Baseline and 6, 12 and 14 weeks after intervention
|
|
Change in 24 h ambulatory blood pressure
Time Frame: Baseline (day 0) and 12 weeks after intervention
|
24 h ambulatory blood pressure will be measured using standard techniques.
|
Baseline (day 0) and 12 weeks after intervention
|
|
Change in metabolic parameters in blood
Time Frame: Baseline (day 0) and 6, 12 and 14 weeks after intervention
|
Metabolic parameters determined in blood included: comprehensive metabolic panel, liver panel and cell blood counting.
|
Baseline (day 0) and 6, 12 and 14 weeks after intervention
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in plasma concentration of cocoa flavanol metabolites
Time Frame: Baseline (day 0) and 6, 12 and 14 weeks after intervention
|
Cocoa flavanol metabolites in plasma include: structurally related (-)-epicatechin metabolites and 5-(3,4-dihydroxyphenyl)-4-valerolactone metabolites
|
Baseline (day 0) and 6, 12 and 14 weeks after intervention
|
|
Change in plasma concentration of methylxanthines
Time Frame: Baseline (day 0) and 6, 12, and 14 weeks after intervention
|
Methylxanthines determined in plasma include: caffeine, theobromine, paraxanthine and theophylline
|
Baseline (day 0) and 6, 12, and 14 weeks after intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Schroeter H, Heiss C, Spencer JP, Keen CL, Lupton JR, Schmitz HH. Recommending flavanols and procyanidins for cardiovascular health: current knowledge and future needs. Mol Aspects Med. 2010 Dec;31(6):546-57. doi: 10.1016/j.mam.2010.09.008. Epub 2010 Sep 18.
- Ottaviani JI, Balz M, Kimball J, Ensunsa JL, Fong R, Momma TY, Kwik-Uribe C, Schroeter H, Keen CL. Safety and efficacy of cocoa flavanol intake in healthy adults: a randomized, controlled, double-masked trial. Am J Clin Nutr. 2015 Dec;102(6):1425-35. doi: 10.3945/ajcn.115.116178. Epub 2015 Nov 4.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2012
Primary Completion (Actual)
December 1, 2012
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
May 15, 2015
First Submitted That Met QC Criteria
May 18, 2015
First Posted (Estimate)
May 19, 2015
Study Record Updates
Last Update Posted (Actual)
May 30, 2017
Last Update Submitted That Met QC Criteria
May 24, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- 311497-II (Other Identifier: UC Davis)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
University of Vermont Medical CenterAvocado Nutrition CenterRecruitingHealthy | Healthy Volunteers | Healthy Subjects | Healthy Volunteer | Healthy Adult | Healthy Volunteers Only | Healthy Male and Female Subjects | Healthy Non-smokersUnited States
-
Dragonfly TherapeuticsRecruitingHealthy | Healthy Participants | Healthy Adult Females | Volunteer | Healthy Adult MaleAustralia
-
University of PalermoCompletedHealthy | Healthy Volunteers | Healthy Subjects | Healthy Participants | Static Stretching | Stretch | StretchingItaly
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Umm Al-Qura UniversityActive, not recruitingHealthy | Healthy Participants | Healthy Adult | Healthy Women | Healthy Adult Females | Healthy Adult Participants | Healthy Young Adults | Healthy Adult Female Participants | Healthy Adult Male | Poor Sleep Quality | Healthy (Controls) | Poor Sleeping Quality | Healthy Adult Male Subjects | Health Adult SubjectsSaudi Arabia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
University of PalermoCompletedHealthy Participants | Healthy Adult Participants | Healthy Young AdultsItaly
-
PfizerNot yet recruitingHealthy | Healthy AdultsUnited States
-
RAGE BioRecruitingHealthy | Healthy SmokerAustralia
Clinical Trials on Control Capsules
-
Maastricht University Medical CenterScelta Mycofriends B.V.; CNC Grondstoffen B.V.Completed
-
Housey Healthcare ULCGlycemic Index Laboratories, IncCompletedInsulin Resistance, DiabetesCanada
-
Radicle ScienceCompletedDepression | Pain | Sleep | AnxietyUnited States
-
PepsiCo Global R&DRecruitingMuscle Damage | MuscleUnited States
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary Disease (COPD)Taiwan, Korea, Republic of, Japan, India, Hong Kong, Singapore
-
BiogenCompletedMultiple SclerosisUnited States
-
IMDEA FoodCompletedImmune System and Related DisordersSpain
-
The Affiliated Hospital of Qingdao UniversityPeking University People's Hospital; Cancer Institute and Hospital, Chinese... and other collaboratorsRecruitingProbiotics | Colorectal AdenomaChina
-
BiogenAbbVieCompletedMItochondrial MyopathiesUnited States, Denmark
-
BiogenTerminatedConnective Tissue Disease-Associated Pulmonary Arterial HypertensionUnited States, Spain, Japan, Australia, United Kingdom, Canada, Germany, Belgium, Argentina, Israel, Mexico, Brazil, Czechia, Netherlands, Philippines